This site is intended for health professionals only
Wednesday 26 October 2016 Instagram
Share |

Diabetes prescriptions shoot to 40m

Diabetes prescriptions shoot to 40m

Diabetes prescriptions shoot to 40m

Diabetes prescriptions topped 40 million for the first time ever last year, official figures show.

Data from the Health and Social Care Information Centre (HSCIC) shows the number of diabetes prescriptions has risen by almost 50% in six years to 40.6 million in 2011/12.

According to the report Prescribing for Diabetes in England: 2005/6 to 2011/12 the net cost of diabetes drugs rose by just under 50% during the same period.

Furthermore, while the overall cost of all drugs to the NHS fell last year by just 1%, the diabetes drugs bill increased by nearly 5%.

“Our figures show diabetes is having a growing impact on prescribing in a very obvious way – from the amount of prescriptions dispensed to patients in primary care to the annual drugs bill costs to the NHS,” said Tim Straughan, Chief Executive of HSCIC.

“Other reports we produce, such as our National Diabetes Audit and the Quality and Outcomes Framework, also demonstrate the impact of diabetes is widespread in all areas of the health service; from pharmacy to hospital care. When all this information is considered together, it presents a full and somewhat concerning picture of the increasing impact of this condition.”

How you do explain the sudden rise in diabetes prescriptions?


I am not surprised with this because the Aviva test strips on their own cost £28.00 for a box of 50 strips and if the patient needs to do 5 tests a day it means each box lasts 10 days. The Aviva accu check machine with 10strips costs £10.00 surely the manufacturer can increase the strips in one box, it is so embarrassing for patients or their parents to be at the GP practice on a weekly basis for a repeat prescription because some practices only do a prescriotion for only one box. It is quite restricting on the clients freedom, if they have to travel ensuring they have enough supplies is very stressful.
With the current state of affairs with the NHS the cost implication can not be overlooked. In return for the offshore tax benefits some of these manufactures of the medical devices can at least increase their quantities.

Ads by Google

You are leaving

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?